Montelukast is a leukotriene receptor antagonist that is used to treat allergy and asthma. It acts as a cysteinyl leukotriene receptor antagonist that blocks the action of leukotrienes and decreases inflammation. This agent is generally well tolerated in clinical practice. Although montelukast is generally considered as a safe drug, it can cause a few adverse drug reactions. In this case study, a rare side effect of montelukast that has been reported only twice before is presented. The importance of this case report is that the youngest patient who had ecchymosis due to the use of montelukast treatment is reported.
1. Günen H. Astım ve alerjik rinit tedavisinde sinerjistik kombinasyon. Göğüs Hastalıkları Serisi 2011;2:1-16.
2. Cingi C, Ozlugedik S. Effects of montelukast on quality of life in patients with persistent allergic rhinitis. Otolaryngol Head Neck Surg 2010;142:654-58.
3. Diamant Z, Mantzouranis E, Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol 2009;5:639-58.
4. Markham A, Faulds D. Montelukast. Drugs 1998;56:251-6.
5. Harrold LR, Patterson K, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmaco-epidemiol Drug Saf 2007;16:620-6.
6. Nayak A, Langdon R. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007;67(6):887-901.
7. Meltzer EO, Lockey RF, Friedman BF, Kalberg C, Goode-Sellers S, Srebro S, et al. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc 2002;77(5):437- 445.
8. Aypak C, Turedi O, Solmaz N, Yikilkan H, Gorpelioglu S. A rare adverse effect of montelukast treatment: ecchymosis. Respir Care2013;58:e104–e106.
9. Béné J, Gantiois E, Landouzy M, Auffret M, Coupé P, Courouble M et al. Ecchymosis during montelukast therapy: about one case. Therapie 2014; 69(6):517-8.
10. Shear NH. Litt’s drug eruption reference manual: including drug inter-actions, 11th edition. London: Informa; 2011:452.